Abstract

Inhibition of Livin Gene Combined with Cisplatin Affect the Apoptosis of Laryngeal Carcinoma Hep-2 Cells by RNA Interference Technique

Highlights

  • Cisplatin(DDP)-based combined chemotherapy regimen is an important method for the treatment of laryngeal carcinoma

  • Ltd.; oligonucleotides, primers, liposome Lipofectamine 2000 and Opti-MEM1 serumfree medium were purchased from Invitrogen company (America); restriction endonuclease, including SalI and BamHI, as well as HindIII T4 ligase, and small Plasmid Extraction Kit, real-time quantitative PCR kit were purchased from Dalian Takara company; mouse anti-human livin monoclonal antibody, Rabbit anti-human β-actin monoclonal antibody and Rabbit anti-rat livin labeled secondary antibody, as well as the Western blot were purchased from Wuhan boster company; cisplatin was purchased from Shandong Qilu pharmaceutical; MTT was purchased from Sigma Co

  • Effect of siRNA interfered livin gene on apoptosis sensitivity of laryngeal cancer cells induced by cisplatin

Read more

Summary

Introduction

Cisplatin(DDP)-based combined chemotherapy regimen is an important method for the treatment of laryngeal carcinoma. Overexpression of inhibitor of apoptosis protein is one of the important reasons for the failure of chemotherapy in tumor cells, and the apoptosis of the cells can be induced by decreasing the activity of the inhibitor of apoptosis protein [2]. As a newly discovered inhibitor of apoptosis protein, is selectively highly expressed in most common human cancer, which closely related to the occurrence and development of tumor and drug resistance [3]. The fact that laryngeal carcinoma cells is not sensitive to cisplatin treatment and high expression of livin has been found in the cell suggested that livin induced apoptosis inhibition may be strongly correlated with the drug resistance of laryngeal carcinoma. There was previous research livin gene silencing can inhibit the invasion of laryngeal cancer cell [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call